CDC42SE2

Across TCGA pan-cancer cohorts, CDC42SE2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CDC42SE2 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDC42SE2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CDC42SE2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where CDC42SE2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.703	0.334	.006	19	view →
HNSC	OS	Tertile	All	0.946	0.778	.009	11	view →
CCRCC	OS	Median	IV	0.256	1.000	.049	4	view →
LUAD	DFS	Tertile	All	0.748	0.422	.023	4	view →
GBM	OS	Quartile	All	0.408	0.611	.020	4	view →
UCEC	OS	Median	All	0.966	0.858	.034	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CDC42SE2–PDAC (OS)

Open the PDAC breakdown →